IRADIMED Posts Mixed Q2: US Growth Offsets International Dip
Ticker: IRMD · Form: 10-Q · Filed: Aug 1, 2025 · CIK: 1325618
| Field | Detail |
|---|---|
| Company | Iradimed CORP (IRMD) |
| Form Type | 10-Q |
| Filed Date | Aug 1, 2025 |
| Risk Level | medium |
| Sentiment | mixed |
Sentiment: mixed
Topics: Medical Devices, Q2 Earnings, Revenue Growth, International Sales, Healthcare Technology, SEC Filing, Financial Performance
Related Tickers: IRMD
TL;DR
IRMD's U.S. growth is solid, but international weakness is a red flag; proceed with caution.
AI Summary
IRADIMED CORP (IRMD) reported a mixed financial performance for the quarter ended June 30, 2025. Revenue from U.S. operations for the three months ended June 30, 2025, increased to $12.5 million from $11.8 million in the prior year period, representing a 5.9% growth. However, international revenue for the same period decreased to $3.2 million from $3.5 million, a decline of 8.6%. For the six months ended June 30, 2025, U.S. revenue grew to $24.8 million from $23.1 million, a 7.4% increase, while international revenue slightly decreased to $6.5 million from $6.6 million, a 1.5% decline. The company's retained earnings as of June 30, 2025, stood at $45.2 million, up from $43.5 million as of March 31, 2025, indicating profitability. Additional paid-in capital also increased to $120.1 million from $119.8 million over the same period. The company continues to invest in property and equipment, with machinery and equipment valued at $8.7 million and computer software and hardware at $2.1 million as of June 30, 2025. Related party transactions with Susi LLC generated $0.3 million in revenue for the three months ended June 30, 2025, and $0.6 million for the six months ended June 30, 2025.
Why It Matters
IRADIMED's mixed Q2 results highlight the challenges medical device companies face in balancing domestic growth with international market volatility. For investors, the 5.9% U.S. revenue growth is a positive signal, but the 8.6% international decline warrants close monitoring, especially given the competitive landscape in medical imaging. Employees might see continued stability in U.S. operations but potential pressure on international teams. Customers benefit from IRADIMED's ongoing investment in equipment and software, suggesting continued product development. The broader market will watch if IRMD can sustain U.S. momentum and reverse international trends against larger competitors like GE Healthcare and Siemens Healthineers.
Risk Assessment
Risk Level: medium — The risk level is medium due to the decline in international revenue by 8.6% for the three months ended June 30, 2025, from $3.5 million to $3.2 million. While U.S. revenue grew by 5.9% to $12.5 million, the international segment's underperformance could impact overall profitability and market expansion, indicating potential headwinds in key global markets.
Analyst Insight
Investors should monitor IRADIMED's next earnings call for strategies to address the international revenue decline and assess if U.S. growth can consistently offset these challenges. Consider holding existing positions but deferring new investments until a clear turnaround in international markets is evident.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $15.7M
- operating Margin
- N/A
- total Assets
- N/A
- total Debt
- N/A
- net Income
- N/A
- eps
- N/A
- gross Margin
- N/A
- cash Position
- N/A
- revenue Growth
- +2.6%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| U.S. Operations | $12.5M | +5.9% |
| International Operations | $3.2M | -8.6% |
| U.S. Operations (YTD) | $24.8M | +7.4% |
| International Operations (YTD) | $6.5M | -1.5% |
| Related Party (Susi LLC) | $0.3M | N/A |
| Related Party (Susi LLC) (YTD) | $0.6M | N/A |
Key Numbers
- $12.5M — U.S. Revenue (Q2 2025) (Increased from $11.8M in Q2 2024, a 5.9% growth.)
- $3.2M — International Revenue (Q2 2025) (Decreased from $3.5M in Q2 2024, an 8.6% decline.)
- $24.8M — U.S. Revenue (YTD Q2 2025) (Increased from $23.1M in YTD Q2 2024, a 7.4% growth.)
- $6.5M — International Revenue (YTD Q2 2025) (Slightly decreased from $6.6M in YTD Q2 2024, a 1.5% decline.)
- $45.2M — Retained Earnings (June 30, 2025) (Increased from $43.5M as of March 31, 2025, indicating profitability.)
- $120.1M — Additional Paid-In Capital (June 30, 2025) (Increased from $119.8M as of March 31, 2025.)
- $0.3M — Related Party Revenue (Q2 2025) (Revenue from Susi LLC for the three months ended June 30, 2025.)
Key Players & Entities
- IRADIMED CORP (company) — filer of the 10-Q
- Susi LLC (company) — related party generating revenue for IRADIMED
- GE Healthcare (company) — competitor in medical imaging
- Siemens Healthineers (company) — competitor in medical imaging
- Bloomberg (company) — publisher of this analysis
- SEC (regulator) — regulator for 10-Q filings
- Orlando, FL (location) — business address of IRADIMED CORP
FAQ
What were IRADIMED CORP's U.S. revenue figures for Q2 2025?
IRADIMED CORP's U.S. revenue for the three months ended June 30, 2025, was $12.5 million, representing a 5.9% increase from $11.8 million in the same period of 2024.
How did IRADIMED CORP's international revenue perform in Q2 2025?
International revenue for IRADIMED CORP decreased to $3.2 million for the three months ended June 30, 2025, down 8.6% from $3.5 million in the prior year period.
What is IRADIMED CORP's retained earnings as of June 30, 2025?
As of June 30, 2025, IRADIMED CORP reported retained earnings of $45.2 million, an increase from $43.5 million as of March 31, 2025.
What was the total U.S. revenue for IRADIMED CORP for the first six months of 2025?
For the six months ended June 30, 2025, IRADIMED CORP's U.S. revenue totaled $24.8 million, an increase from $23.1 million in the comparable period of 2024.
Did IRADIMED CORP have any related party transactions in Q2 2025?
Yes, IRADIMED CORP generated $0.3 million in revenue from related party transactions with Susi LLC for the three months ended June 30, 2025.
What is the significance of the international revenue decline for IRADIMED CORP?
The 8.6% decline in international revenue for IRADIMED CORP in Q2 2025 indicates potential challenges in global markets, which could impact the company's overall growth strategy and market share against competitors.
How does IRADIMED CORP's Q2 2025 performance impact investors?
Investors should note the mixed performance, with strong U.S. growth offset by international declines. This suggests a need to evaluate the company's ability to diversify revenue streams and mitigate international market risks.
What are IRADIMED CORP's key assets in property and equipment as of June 30, 2025?
As of June 30, 2025, IRADIMED CORP's key property and equipment assets included machinery and equipment valued at $8.7 million and computer software and hardware at $2.1 million.
What is the primary business of IRADIMED CORP?
IRADIMED CORP operates in the surgical and medical instruments and apparatus industry, providing medical technology solutions.
What was the change in IRADIMED CORP's additional paid-in capital from March 31, 2025, to June 30, 2025?
IRADIMED CORP's additional paid-in capital increased from $119.8 million as of March 31, 2025, to $120.1 million as of June 30, 2025.
Industry Context
IRADIMED CORP operates in the surgical and medical instruments and apparatus industry. This sector is characterized by innovation, regulatory oversight, and a need for continuous investment in research and development. Competition can be intense, with both large established players and smaller specialized firms vying for market share.
Regulatory Implications
As a medical device company, IRADIMED CORP is subject to stringent regulations from bodies like the FDA. Compliance with quality standards, manufacturing practices, and product approvals is critical. Any changes in regulatory requirements or enforcement could impact product development timelines, market access, and overall financial performance.
What Investors Should Do
- Monitor international revenue trends closely.
- Analyze the drivers of U.S. revenue growth.
- Evaluate the significance of related party transactions.
- Review capital expenditure plans.
Key Dates
- 2025-06-30: Quarterly Report Filing (10-Q) — Provides updated financial performance and operational details for the period ending June 30, 2025.
- 2025-03-31: End of First Quarter — Marks the end of the first quarter of 2025, with retained earnings reported at $43.5M.
- 2024-06-30: Prior Year Quarter End — Provides a comparative baseline for Q2 2025 revenue figures ($11.8M U.S., $3.5M International).
Glossary
- Retained Earnings
- The cumulative amount of net income that a company has retained over time, rather than distributing as dividends. (An increase in retained earnings, from $43.5M to $45.2M, indicates ongoing profitability for IRADIMED CORP.)
- Additional Paid-In Capital
- The amount of capital a company has received from investors in exchange for stock, above the stock's par value. (An increase in this account, from $119.8M to $120.1M, suggests potential stock issuance or other equity transactions.)
- Machinery and Equipment
- Tangible assets used in the production of goods or services, or for administrative purposes. (The company's investment in machinery and equipment, valued at $8.7M, reflects its operational capacity and capital expenditures.)
- Computer Software and Hardware
- Assets related to the company's information technology infrastructure. (The valuation of $2.1M indicates investment in technology essential for operations and potentially product development.)
- Related Party Transactions
- Transactions between a company and its related parties, such as affiliated companies or key management personnel. (Revenue of $0.3M from Susi LLC highlights transactions with entities that may have common control or influence.)
Year-Over-Year Comparison
Compared to the previous year's filings, IRADIMED CORP shows a mixed performance. U.S. revenue has seen consistent growth, with Q2 2025 up 5.9% and YTD up 7.4%. However, international revenue has experienced a decline, down 8.6% in Q2 and 1.5% YTD. Retained earnings have increased, indicating profitability, and additional paid-in capital has also seen a slight rise, suggesting ongoing equity activity. No significant new risks or changes in financial highlights like net income or margins were detailed in the provided summary.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 1, 2025 regarding IRADIMED CORP (IRMD).